Testing TGRX-1942 for advanced solid tumors and blood cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase I study evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of TGRX-1942 in patients with advanced solid tumors and relapsed or refractory hematologic malignancies. The study is structured in three parts: dose escalation, dose expansion, and indication expansion phases. Initially, patients with advanced solid tumors will be enrolled, and later, those with specific gene mutations or other hematological malignancies may be included based on the results of the dose escalation phase.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* For dose escalation phase, patient is diagnosed with advanced/metastatic solid tumor who had failed standard therapies and does not have available effective treatment, or who relapsed from prior treatments
* ECOG score of equals to or lower than 1
* Life expectancy of at least 3 months
* Adequate systemic and organ functions, including hematologic, hepatic and kidney functions
* Willing to provide available tumor biopsy sample or reports, or willing to undergo tumor biopsy examination, and willing to partake whole blood sampling for evaluations
* For female of child-bearing potential, willing to undergo plasma pregnancy test 28 days before first dose and have negative results
* Male and Female of child-bearing potential must agree to take effective contraceptive measures during the entire treatment period and for 2 months after the end of treatment
* Understand and willing to sign informed concent; willing and able to complete the visiting schedule and other tasks as required for the study

Exclusion Criteria:

* Allergic to any of the ingredient of the investigational drug
* History of other primary malignancies
* Have adverse/toxic effects from previous treatment that has not recovered to CTCAE 5.0 \<= Grade 1
* Received other anti-tumor treatments (i.e., chemotherapy, biologics, immunotherapy, targeted therapy, etc.) 28 days before first dose, or radiation therapy 14 days before first dose
* Used drugs known to significantly affect P450 metabolism 2 weeks before first dose
* Participated in other clinical trials and used other investigational agents 28 days before first dose
* Received major surgeries or had traumatic injuries 28 days before first dose
* Need to use concomitant drugs that could cause QTc elongation or induce Torsades de Pointes
* History or presence of other medical conditions, such as HIV/HBV/HCV positive; received anticoagulation treatment; coagulation dysfunction; major or clinically significant cardiovascular disease; pneumonia; clinically significant gastrointestinal abnormalities that could affect drug absorption; uncontrollable hypertension; ulcer in abdomen, intestine, stomach, trachea or esophagus; uncontrolled seizure or have other central nervous system diseases, poorly managed diabetes; long QT syndrome; uncontrolled active infections; uncontrolled pericardial or abdominal effusion; adrenaline malfunction; thyroid dysfunction; severe unhealed wound, ulcer or bone fractures; Toxic epidermal necrolysis; Stevens-Johnson syndrome
* Have symptomatic or uncontrolled primary or metastatic central nervous system tumor or Leptomeninges tumor, or untreated diseases that cause compressions to spinal cords
* For female patients: in pregnancy or breast-feeding periods
* Presence of any condition or history that could affect study results or participation to the study in the judgement of the investigator
* Used immunosuppressant drugs within14 days before first dose
* Received vaccine injection within 30 days of Cycle 1 Day 1

Where it's running

• Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Principal investigator: panhongming@zju.edu.cn Pan, MD — Zhejiang University School of Medicine Sir Run Run Shaw Hospital
• Study coordinator: Hongming Pan, MD
• Email: panhongming@zju.edu.cn
• Phone: 86-0571-86006926

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• First-in-human test of BLU-924 for KRAS-mutant advanced cancers

  This trial tests BLU-924 in adults with KRAS-mutant advanced solid tumors, including PDAC, NSCLC, and CRC, to see if it is safe and may help control cancer.

  Recruiting at 3 sites Phase 1/2 Blueprint Medicines Corporation · Sarasota, Florida and 15 other locations · NCT07629960

• LY4052031 for advanced or metastatic urothelial and other nectin‑4–expressing solid tumors

  This trial will test whether LY4052031 is safe and can help people with advanced or metastatic urothelial cancer or other solid tumors that express nectin‑4.

  Recruiting at 36 sites Phase 1 Eli Lilly and Company · Duarte, California and 39 other locations · NCT06465069

• Oral Alintegimod with Ipilimumab followed by Nivolumab for advanced cancer

  This study is testing if a new oral medication called Alintegimod, combined with two other cancer treatments, can help people with advanced solid tumors feel better and live longer.

  Recruiting at 4 sites Phase 1/2 7 Hills Pharma, LLC · Aurora, Colorado and 4 other locations · NCT06362369

• Testing MGC026 in patients with advanced solid tumors

  This study is testing a new treatment called MGC026 to see if it can help adults with advanced solid tumors that can't be removed or have spread to other parts of the body.

  Recruiting at 12 sites Phase 1 MacroGenics · Los Angeles, California and 11 other locations · NCT06242470

• Testing a new treatment for advanced solid tumors

  This study is testing a new treatment called tolododekin alfa for people with advanced solid tumors that haven't improved with standard therapies to see how safe it is and how well it works.

  Recruiting at 5 sites Phase 1 Ankyra Therapeutics, Inc · Bethesda, Maryland and 4 other locations · NCT06171750

• Monoclonal antibody treatment for advanced solid tumors

  This study is testing a new antibody treatment for people with advanced solid tumors to see if it is safe and effective on its own or when combined with another cancer drug.

  Recruiting at 4 sites Phase 1/2 OncoResponse, Inc. · Austin, Texas and 3 other locations · NCT06090266

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.